Dexcom (DXCM) Receives New Coverage from Analysts at Guggenheim

Guggenheim initiated coverage on shares of Dexcom (NASDAQ:DXCM) in a research report sent to investors on Tuesday, MarketBeat reports. The brokerage issued a neutral rating on the medical device company’s stock.

DXCM has been the subject of several other reports. Zacks Investment Research lowered shares of Dexcom from a hold rating to a sell rating in a report on Friday, March 2nd. BMO Capital Markets raised shares of Dexcom to an outperform rating and set a $78.00 price objective for the company in a report on Thursday, March 29th. Piper Jaffray set a $80.00 price objective on shares of Dexcom and gave the company a buy rating in a report on Thursday, March 29th. BidaskClub lowered shares of Dexcom from a strong-buy rating to a buy rating in a report on Friday, December 22nd. Finally, Robert W. Baird raised shares of Dexcom from a neutral rating to an outperform rating and set a $58.00 price objective for the company in a report on Friday, March 23rd. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and a consensus target price of $66.91.

How to Become a New Pot Stock Millionaire

Dexcom stock opened at $70.15 on Tuesday. Dexcom has a 12-month low of $42.62 and a 12-month high of $81.91. The company has a current ratio of 5.36, a quick ratio of 5.04 and a debt-to-equity ratio of 0.78.

Dexcom (NASDAQ:DXCM) last released its earnings results on Tuesday, February 27th. The medical device company reported $0.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.07. The company had revenue of $221.00 million during the quarter, compared to analyst estimates of $217.82 million. Dexcom had a negative net margin of 6.99% and a negative return on equity of 13.99%. equities research analysts predict that Dexcom will post -0.56 EPS for the current fiscal year.

In other news, EVP Richard Doubleday sold 2,581 shares of the stock in a transaction that occurred on Friday, March 23rd. The stock was sold at an average price of $68.44, for a total transaction of $176,643.64. Following the completion of the transaction, the executive vice president now directly owns 94,429 shares in the company, valued at approximately $6,462,720.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Terrance H. Gregg sold 10,000 shares of the stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $65.51, for a total value of $655,100.00. Following the transaction, the insider now owns 521,674 shares of the company’s stock, valued at $34,174,863.74. The disclosure for this sale can be found here. Insiders have sold a total of 35,854 shares of company stock valued at $2,141,081 over the last quarter. Corporate insiders own 1.70% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of DXCM. American International Group Inc. bought a new position in shares of Dexcom during the 4th quarter valued at approximately $116,000. Thompson Davis & CO. Inc. bought a new position in shares of Dexcom during the 4th quarter valued at approximately $137,000. Zions Bancorporation boosted its position in shares of Dexcom by 36,222.2% during the 3rd quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock valued at $160,000 after acquiring an additional 3,260 shares during the last quarter. Marco Investment Management LLC bought a new position in shares of Dexcom during the 4th quarter valued at approximately $201,000. Finally, D.A. Davidson & CO. bought a new position in shares of Dexcom during the 4th quarter valued at approximately $208,000.

WARNING: “Dexcom (DXCM) Receives New Coverage from Analysts at Guggenheim” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3338223/dexcom-dxcm-receives-new-coverage-from-analysts-at-guggenheim.html.

About Dexcom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Analyst Recommendations for Dexcom (NASDAQ:DXCM)

Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Franklin Templeton Investments Sees Unusually Large Options Volume
Franklin Templeton Investments Sees Unusually Large Options Volume
Traders Buy High Volume of Lumber Liquidators Put Options
Traders Buy High Volume of Lumber Liquidators Put Options
Multi-Color  Earns Media Sentiment Rating of 0.33
Multi-Color Earns Media Sentiment Rating of 0.33
Air Transport Services Group  Receives News Impact Rating of 0.15
Air Transport Services Group Receives News Impact Rating of 0.15
Merck & Co.  Upgraded at Morgan Stanley
Merck & Co. Upgraded at Morgan Stanley
MSC Industrial Direct Target of Unusually High Options Trading
MSC Industrial Direct Target of Unusually High Options Trading


Leave a Reply

© 2006-2018 Ticker Report. Google+.